Semzuvolimab
As of the edition of 20 October 2026, Semzuvolimab is an antibody: stopped in 2025; acts on CD4.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2025
- Kind
- Antibody
- Registered trials
- 14, 3 stopped early
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CD4 | T-cell surface glycoprotein CD4 | P01730 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 3 | 2 | 0 | 0 |
| Phase 2 | 9 | 4 | 1 | 2 |
| Phase 3 | 2 | 0 | 0 | 1 |
| All trials | 14 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| United Biomedical | Lead sponsor of trials | 2010 to now |
| United Therapeutics | Lead sponsor of trials | 2015 to now |
| UBP Greater | Lead sponsor of trials | 2023 to now |